HCG (Human Chorionic Gonadotropin): The Complete Guide

Overview

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone composed of two subunits: an alpha (α) subunit shared with luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH); and a unique beta (β) subunit that confers its biological specificity. The hormone is naturally produced in large quantities by the syncytiotrophoblast cells of the placenta during pregnancy, where it maintains the corpus luteum and supports progesterone production in early gestation (Cole, 2010).

Outside of pregnancy, HCG has significant clinical applications because of its structural similarity to LH. When administered exogenously, HCG binds to the LH/CG receptor on Leydig cells in the testes, stimulating testosterone production and supporting spermatogenesis. This LH-mimicking property is the basis for its use in male hypogonadism, fertility treatment, and as adjunctive therapy during testosterone replacement therapy (Lee et al., 2005).

HCG has been used in clinical medicine for decades. Pharmaceutical-grade HCG products (such as Pregnyl and Novarel) are FDA-approved for specific indications including female infertility, male hypogonadotropic hypogonadism, and prepubertal cryptorchidism. However, its widespread use as co-therapy with TRT is off-label — supported by clinical evidence and practice guidelines but not formally approved for that specific indication.

The regulatory landscape for HCG changed significantly in 2020 when the FDA reclassified it from a drug to a biologic under the Biologics Price Competition and Innovation Act (BPCIA). This reclassification had practical consequences: compounding pharmacies could no longer produce HCG under standard drug compounding rules, limiting patient access and increasing costs. The reclassification remains a source of ongoing discussion in the TRT and fertility communities.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

The Hypothalamic-Pituitary-Gonadal (HPG) Axis

To understand HCG's mechanism, it is necessary to understand the HPG axis — the hormonal feedback loop that controls testosterone production:

1. Hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulsatile fashion
2. Anterior pituitary responds by releasing LH and FSH
3. LH acts on Leydig cells in the testes to stimulate testosterone synthesis
4. FSH acts on Sertoli cells to support spermatogenesis
5. Testosterone feeds back to the hypothalamus and pituitary, suppressing GnRH and LH/FSH release

When a man takes exogenous testosterone (TRT), the elevated blood testosterone levels signal the hypothalamus and pituitary to shut down GnRH and LH/FSH production. Without LH stimulation, the Leydig cells become quiescent — intratesticular testosterone drops, spermatogenesis declines, and the testes physically atrophy over time (Coviello et al., 2008).

HCG as an LH Mimic

HCG binds to the LH/CG receptor (LHCGR) on Leydig cells with high affinity. Structurally, its α subunit is identical to that of LH, while its β subunit is sufficiently similar (~85% homologous) to activate the same receptor. Upon binding, HCG triggers the same intracellular signaling cascade as LH:

• Activation of adenylyl cyclase → increased cyclic AMP (cAMP)
• Activation of protein kinase A (PKA)
• Upregulation of steroidogenic enzymes (StAR, CYP11A1, CYP17A1)
• Conversion of cholesterol to pregnenolone, then through the steroidogenic pathway to testosterone

The key practical difference between LH and HCG is half-life: LH has a half-life of approximately 20 minutes, while HCG has a half-life of approximately 24–36 hours. This longer half-life makes HCG suitable for clinical use with injections every 2–3 days rather than the pulsatile delivery that would be required to mimic endogenous LH (Cole, 2010).

Maintaining Intratesticular Testosterone (ITT)

Intratesticular testosterone (ITT) concentrations are approximately 50–100 times higher than serum testosterone levels. This high local concentration is essential for spermatogenesis. When exogenous testosterone suppresses LH, ITT drops dramatically — often by 94% or more — even while serum testosterone remains in the normal range from the exogenous supply (Coviello et al., 2008).

Coviello et al. demonstrated that co-administration of HCG at doses of 125–500 IU every other day could maintain ITT at or near baseline levels in men receiving exogenous testosterone. At 250 IU every other day, ITT was maintained at approximately 25% of baseline; at 500 IU every other day, ITT was maintained at approximately 7% above baseline. This dose-dependent preservation of ITT is the physiological basis for using HCG as TRT co-therapy (Coviello et al., 2008).

Supporting Spermatogenesis

By maintaining ITT, HCG helps preserve spermatogenesis during TRT. While ITT alone is not sufficient for full spermatogenesis (FSH is also required for optimal Sertoli cell function), the maintenance of some ITT via HCG prevents the complete cessation of sperm production that typically occurs with TRT alone. Studies have shown that HCG co-therapy can maintain sperm counts in the oligospermic range rather than the azoospermic range typically seen with TRT monotherapy (Lee et al., 2005).

Additional Effects

• Testicular volume: HCG prevents or attenuates the testicular atrophy associated with TRT by maintaining Leydig cell activity and seminiferous tubule function
• Estrogen production: HCG stimulates aromatase activity in Leydig cells, which can increase estradiol (E2) levels. This is an important consideration and a source of side effects (see Side Effects tab)
• Pregnenolone and DHEA: HCG-stimulated steroidogenesis produces upstream neurosteroid precursors (pregnenolone, DHEA) that may contribute to improved well-being reported by some patients on HCG co-therapy

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Intratesticular Testosterone Preservation (Coviello et al.)

The landmark study by Coviello et al. at Massachusetts General Hospital quantified HCG's ability to maintain intratesticular testosterone (ITT) in men receiving exogenous testosterone. Twenty-nine healthy men with normal reproductive function received testosterone enanthate (200 mg IM weekly) plus varying doses of HCG (0, 125, 250, or 500 IU every other day) for three weeks (Coviello et al., 2008).

Key findings:

• Without HCG, ITT decreased by 94% (from baseline ~600 ng/dL intratesticular to ~30 ng/dL)
• HCG 125 IU EOD maintained ITT at ~25% of baseline
• HCG 250 IU EOD maintained ITT at ~25% of baseline
• HCG 500 IU EOD maintained ITT at ~7% above baseline
• Dose-dependent response confirmed: higher HCG doses preserved more ITT

This study provided the pharmacological rationale for HCG co-therapy with TRT that is now widely practiced in men's health clinics.

Fertility Preservation During TRT (Lee & Coughlin)

Lee and Coughlin reviewed the role of HCG in male hypogonadotropic hypogonadism and TRT-associated fertility impairment. Their analysis established that HCG monotherapy can restore testosterone levels in men with secondary hypogonadism and that HCG co-administration during TRT can help maintain spermatogenesis (Lee et al., 2005).

The clinical data showed that men who received HCG alongside TRT were more likely to maintain some degree of spermatogenesis compared to TRT alone, though full recovery of sperm parameters often required cessation of TRT and/or addition of FSH.

Angiogenesis and Tissue Effects (Hsieh et al.)

Hsieh et al. investigated HCG's role in promoting angiogenesis and tissue remodeling in the context of reproductive physiology. Their work demonstrated that HCG activates angiogenic pathways through VEGF upregulation, supporting corpus luteum vascularization during pregnancy. While these effects are primarily relevant to reproductive physiology, they contribute to understanding HCG's broader biological actions (Hsieh et al., 2013).

Cryptorchidism Treatment

HCG has been used for decades to treat prepubertal cryptorchidism (undescended testes). By stimulating Leydig cell testosterone production, HCG can promote testicular descent in some cases, reducing the need for surgical orchiopexy. Response rates vary by study, typically ranging from 10–50% depending on patient selection and dosing protocol. This remains an FDA-approved indication (Lee et al., 2005).

HCG Monotherapy for Hypogonadism

Several studies have evaluated HCG as monotherapy for male hypogonadism — using it to stimulate the testes to produce more testosterone endogenously rather than supplying exogenous testosterone. This approach preserves fertility because it maintains the HPG axis function (albeit through bypassing the pituitary with exogenous LH-like stimulation). Studies report testosterone increases of 200–300 ng/dL on average with HCG monotherapy protocols, though responses are variable and dependent on baseline Leydig cell function (Lee et al., 2005).

Limitations and Gaps

• No large RCTs for TRT co-therapy: While HCG co-therapy with TRT is widely practiced, no large randomized controlled trials have been conducted specifically evaluating long-term fertility outcomes with this protocol
• Dose optimization: Optimal HCG dosing for TRT co-therapy has not been standardized through Phase 3 trials — protocols are based on the Coviello data and clinical experience
• Long-term data: Long-term (multi-year) safety and efficacy data for HCG co-therapy is limited to clinical experience and retrospective analyses rather than prospective trials

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indications

Common Off-Label Uses

What HCG Is NOT Used For

• Weight loss: HCG has been promoted as a weight loss agent in the "HCG diet" — a protocol combining very low calorie intake (500 kcal/day) with HCG injections. There is no credible evidence that HCG promotes weight loss beyond the effects of caloric restriction alone. The FDA, the American Medical Association, and the American Society of Bariatric Physicians have all stated that HCG is ineffective for weight loss. See the Q&A tab for a detailed analysis.
• Athletic performance enhancement: While HCG can stimulate testosterone production, it is not a direct performance-enhancing agent. It is prohibited by WADA in males as a means of maintaining endogenous testosterone during or after steroid use.
• Anti-aging: HCG is sometimes marketed in anti-aging clinics alongside other hormones. Its role in anti-aging is not supported by clinical evidence beyond its testosterone-stimulating properties.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Commonly Reported Protocols

Dosing protocols above are derived from published clinical research and established medical practice. Key references: Coviello et al., 2008 (JCEM) · Lee et al., 2005 (Endocrinology Reviews)

Administration

HCG is supplied as a lyophilized powder that requires reconstitution with bacteriostatic water or sodium chloride solution before injection. Once reconstituted, it is typically administered subcutaneously (SC) in the abdominal fat using a small insulin-type syringe (29–31 gauge). Intramuscular (IM) injection is also used, particularly for higher-volume doses.

• Subcutaneous (preferred for co-therapy): Injected into abdominal fat, rotating injection sites. Less painful, easier to self-administer, and generally preferred for the lower volumes used in TRT co-therapy.
• Intramuscular: Injected into the deltoid or gluteal muscle. More commonly used for larger-volume fertility doses.

Laboratory Monitoring

Patients on HCG should have regular bloodwork to monitor:

• Total and free testosterone: To assess therapeutic response
• Estradiol (E2): HCG stimulates aromatase, which can increase E2. Elevated E2 can cause gynecomastia, water retention, and mood changes. Many clinicians monitor E2 and may co-prescribe an aromatase inhibitor (AI) if E2 rises above the target range
• LH and FSH: Suppressed on TRT; useful to assess HPG axis function during HCG monotherapy or restart protocols
• Semen analysis: If fertility preservation is a treatment goal
• Hematocrit/hemoglobin: Testosterone-stimulated erythropoiesis can increase red blood cell count

Storage

• Unreconstituted powder: Store at room temperature or refrigerated per manufacturer instructions
• Reconstituted solution: Refrigerate (2–8°C / 36–46°F). Use within 30–60 days depending on diluent (bacteriostatic water extends stability). Discard if solution becomes cloudy

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Patients Report

Reported Timeline

Sources: Coviello et al., 2008 — Low-dose HCG maintains intratesticular testosterone during TRT · Lee & Ramasamy, 2012 — Concomitant HCG preserves spermatogenesis during TRT · Patel et al., 2018 — Indications for HCG use in male hypogonadism management

Commonly Reported Benefits

• Maintained testicular size: The most consistently reported benefit. Men who had noticed testicular shrinkage on TRT report restoration of volume after adding HCG
• Preserved ejaculate volume: Closely related to ITT and seminal vesicle function
• Improved sense of well-being: Many patients describe feeling "better" on TRT+HCG than on TRT alone, which may relate to upstream neurosteroid production
• Maintained fertility: Men who later attempt conception while on TRT+HCG may have better baseline spermatogenesis than those on TRT alone

Important Context

• Placebo effect: Some reported benefits (mood, energy, libido) may partly reflect expectation effects
• Variable response: Not all men respond equally to HCG. Leydig cell reserve and baseline gonadal function influence the degree of ITT preservation
• Side effects may offset benefits: Estradiol elevation from HCG can cause water retention, mood swings, and gynecomastia that may reduce net perceived benefit

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Common Side Effects

Serious / Rare Side Effects

• Ovarian hyperstimulation syndrome (OHSS): A potentially life-threatening complication in women undergoing fertility treatment with HCG. Characterized by ovarian enlargement, fluid accumulation in the abdomen and chest, and potentially thromboembolic events. Not applicable to male use at typical co-therapy doses.
• Thromboembolic events: Rare reports of venous thromboembolism associated with HCG use, primarily in the fertility treatment context. The absolute risk in male co-therapy protocols is not well-quantified but appears very low.
• Precocious puberty: A risk specific to pediatric use for cryptorchidism — early activation of pubertal development from HCG-stimulated testosterone.

Estradiol Management

Estradiol elevation is the most practically important side effect of HCG in the TRT co-therapy context. HCG stimulates both testosterone and estradiol production in the testes. Management approaches include:

• Dose reduction: Lowering the HCG dose reduces aromatase substrate and E2 production
• Aromatase inhibitor (AI): Low-dose anastrozole (0.25–0.5 mg 2–3x/week) is commonly co-prescribed. However, AI use is itself controversial, with concerns about bone density, lipid profiles, and cognitive effects from excessive estradiol suppression
• Injection frequency adjustment: More frequent, smaller doses may produce more stable hormone levels than less frequent, larger doses
• Lab monitoring: Regular estradiol testing guides dose adjustments. Target ranges vary by clinician, but sensitive E2 levels of 20–40 pg/mL are commonly targeted in men

Contraindications

• Hormone-sensitive cancers: Prostate cancer, breast cancer, or other androgen/estrogen-sensitive malignancies
• Precocious puberty: Contraindicated when premature sexual development is a concern
• Pregnancy (exogenous): Though HCG is naturally produced during pregnancy, exogenous administration is not indicated outside of specific fertility protocols
• Known hypersensitivity to HCG or any excipient

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA-Approved Products

The 2020 Biologic Reclassification

The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the Affordable Care Act in 2010, included a provision to transition certain protein products (including HCG) from regulation as drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) to regulation as biologics under the Public Health Service Act (PHSA). This transition took effect on March 23, 2020.

Practical consequences of the reclassification:

• Compounding pharmacies lost the ability to compound HCG under Section 503A and 503B of the FDCA. Biologic products have different compounding rules, and no pathway existed for routine compounding of HCG after reclassification.
• Patient cost increased: Compounded HCG was typically $50–$100/month. Brand-name pharmaceutical HCG costs $150–$400+ per month, depending on dose and insurance coverage.
• Access reduced: Many TRT clinics that had relied on compounding pharmacies for affordable HCG were forced to source from pharmaceutical manufacturers at higher cost, often passing costs to patients.
• Some compounding pharmacies continued temporarily under FDA enforcement discretion during the COVID-19 pandemic, but this was not a permanent solution.

Ongoing Compounding Issues

The loss of compounding access remains a significant issue for the TRT community. Legislative and regulatory efforts have been made to restore compounding pharmacies' ability to produce HCG, including proposed bills and FDA guidance updates. The situation continues to evolve, and patients should consult their providers for current availability options.

WADA Status

HCG is prohibited by WADA under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) for male athletes. It is banned both in-competition and out-of-competition because it can be used to stimulate endogenous testosterone production during or after anabolic steroid use, effectively masking steroid abuse. HCG is not prohibited for female athletes unless used as a masking agent.

DEA Status

HCG is not a DEA-scheduled controlled substance. It is a prescription medication that requires a valid prescription from a licensed healthcare provider, but it does not carry the scheduling restrictions associated with testosterone (Schedule III) or other controlled substances.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

Insurance coverage for HCG is inconsistent:

• Fertility treatment: May be covered under fertility benefits (state-dependent). Many states mandate some fertility coverage, which may include HCG as a trigger shot or fertility treatment component.
• Male hypogonadism: Rarely covered for off-label TRT co-therapy. May be covered with prior authorization if prescribed for FDA-approved hypogonadotropic hypogonadism.
• Out-of-pocket: Most men using HCG as TRT co-therapy pay out-of-pocket. Costs vary significantly by pharmacy and geographic region.

Cost Impact of 2020 Reclassification

Before the 2020 reclassification, compounded HCG was the most affordable option for TRT co-therapy patients, typically costing $50–$100/month for standard dosing protocols. The elimination of compounding access forced patients to brand-name products at 2–4 times the cost, or to discontinue HCG from their TRT protocol entirely. This cost increase disproportionately affected men without fertility-specific insurance coverage.

Cost Comparison: HCG vs. Related Treatments

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: HCG helps with weight loss.

Answer: No. The "HCG diet" — a protocol combining HCG injections or drops with a 500 kcal/day diet — has been promoted since the 1950s following a paper by Albert Simeons. However, multiple controlled studies have found no difference in weight loss between HCG and placebo when caloric intake is held constant. A meta-analysis of clinical trials concluded that HCG has no effect on fat distribution, hunger suppression, or metabolic rate beyond what caloric restriction alone produces (Lijesen et al., 1995).

The FDA has stated that "HCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity" and has taken enforcement action against companies marketing over-the-counter HCG products for weight loss. Any weight loss observed on the HCG diet is attributable to the extreme caloric restriction (500 kcal/day), not to the HCG itself. A 500 kcal/day diet carries its own health risks including muscle loss, gallstones, electrolyte imbalances, and nutritional deficiencies.

Question: Does HCG increase testosterone?

Answer: Yes. HCG stimulates Leydig cells to produce testosterone by mimicking LH. In men with functional testes, HCG administration reliably increases serum testosterone levels. The magnitude of increase depends on baseline Leydig cell function and dose. In men with secondary hypogonadism, HCG monotherapy can increase testosterone by 200–300 ng/dL on average. In men already on TRT, HCG primarily maintains intratesticular testosterone rather than significantly raising serum levels further, since the exogenous testosterone is already providing the systemic supply (Coviello et al., 2008).

Question: Can I stay fertile while on TRT if I take HCG?

Answer: HCG significantly improves the chances of maintaining some spermatogenesis during TRT, but it does not guarantee full fertility preservation. By maintaining intratesticular testosterone, HCG prevents the complete spermatogenic shutdown that typically occurs with TRT alone. However, optimal spermatogenesis requires both adequate ITT and FSH signaling. For men with an active desire to conceive, the standard recommendation is to discontinue TRT and use a combination of HCG and/or SERMs (clomiphene) with or without FSH to restore full spermatogenesis (Lee et al., 2005).

Question: Will HCG reverse testicular atrophy?

Answer: In most cases, HCG can reverse or significantly improve TRT-induced testicular atrophy. Testicular volume on TRT decreases primarily because Leydig cells and seminiferous tubules become quiescent without LH/FSH stimulation. HCG reactivates Leydig cell function and indirectly supports some seminiferous tubule activity. Most men notice improved testicular fullness within 2–4 weeks of starting HCG co-therapy. Complete reversal may take longer and depends on the duration and severity of prior suppression.

Question: Is HCG the same as the pregnancy hormone?

Answer: Yes — pharmaceutical HCG is the same molecule produced naturally during pregnancy. Urinary-derived HCG products (Pregnyl, Novarel) are purified from the urine of pregnant women. Recombinant HCG (Ovidrel / choriogonadotropin alfa) is produced via genetic engineering to match the natural molecule. The fact that HCG is a "pregnancy hormone" does not mean it is estrogenic or feminizing when used in males — its primary effect in men is to stimulate testosterone production by mimicking LH (Cole, 2010).

Question: Why can I no longer get HCG from a compounding pharmacy?

Answer: In 2020, the FDA reclassified HCG from a drug to a biologic under the Biologics Price Competition and Innovation Act (BPCIA). Biologic products have different compounding rules than drugs, and the standard drug compounding pathways (503A/503B) used by compounding pharmacies to produce HCG no longer applied. This effectively ended most compounding pharmacy production of HCG. The reclassification was not based on safety concerns with compounded HCG — it was a statutory transition that had been planned since the BPCIA's enactment in 2010. Efforts to restore compounding access through legislative or regulatory action continue.

Question: Can I use HCG instead of TRT?

Answer: HCG monotherapy is an option for some men with secondary hypogonadism (pituitary/hypothalamic origin) whose testes still have the capacity to produce testosterone. Advantages include maintained fertility and endogenous testosterone production. Disadvantages include less consistent testosterone levels compared to exogenous TRT, the need for more frequent injections, and higher estradiol production per unit of testosterone generated. HCG monotherapy is less effective in men with primary hypogonadism (testicular failure) since it requires functional Leydig cells to work (Lee et al., 2005).

Myth: HCG drops and homeopathic HCG are effective.

Answer: No. Over-the-counter HCG drops, pellets, and sprays marketed for weight loss are either homeopathic preparations (containing no detectable HCG) or mislabeled products. The FDA has taken enforcement action against numerous companies selling such products. Legitimate HCG is a prescription injectable medication that requires proper reconstitution and administration. Oral HCG is destroyed by gastric acid and is not bioavailable — sublingual and oral preparations have no established efficacy.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• HCG is a glycoprotein hormone that mimics luteinizing hormone (LH) by binding to the LH/CG receptor on Leydig cells, stimulating testosterone production and supporting spermatogenesis.
• Its primary clinical role in men's health is TRT co-therapy — maintaining intratesticular testosterone, preserving fertility potential, and preventing testicular atrophy during exogenous testosterone use.
• The evidence base is well-established. Unlike many peptides, HCG has decades of clinical use, FDA-approved indications, and specific clinical studies (Coviello et al., Lee et al.) demonstrating its efficacy for ITT preservation and gonadal stimulation.
• The 2020 FDA reclassification as a biologic disrupted compounding pharmacy access, increased costs, and reduced availability for many TRT co-therapy patients. This reclassification was statutory, not safety-driven.
• Common side effects are estradiol-related: gynecomastia, water retention, and mood changes — all dose-dependent and manageable with monitoring and dose adjustment.
• The "HCG diet" is not supported by evidence. Multiple controlled trials and a meta-analysis have found no weight loss benefit from HCG beyond caloric restriction alone. The FDA considers HCG ineffective for weight loss.
• Typical dosing for TRT co-therapy is 500–1,500 IU subcutaneously 2–3 times per week, adjusted based on laboratory monitoring (testosterone, estradiol) and clinical response.
• Cost ranges from $50–$200/month depending on the source, with insurance coverage variable and often limited to approved indications.

Questions to Ask a Provider

• Given my TRT protocol, what HCG dose and frequency would you recommend to maintain fertility/testicular function?
• How will you monitor estradiol levels, and what is your approach to managing E2 elevations?
• Is HCG monotherapy an option for my situation, or do I need exogenous TRT as well?
• What is the current availability and sourcing for HCG given the biologic reclassification?
• If I want to conceive, should I continue TRT+HCG or switch to a fertility-focused protocol?
• What are the realistic expectations for spermatogenesis maintenance on this protocol?

Sources & Further Reading

Core Clinical Studies

• Coviello AD, Matsumoto AM, Bremner WJ, et al. (2008) — "Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression" — Journal of Clinical Endocrinology & Metabolism
• Lee PA, Coughlin MT (2005) — "Fertility after bilateral cryptorchidism: Evaluation by paternity, hormone, and semen data" — Hormone Research in Paediatrics
• Hsieh M, Zamah AM, Hunzicker-Dunn M (2013) — "Luteinizing hormone receptor signaling and regulation" — Trends in Endocrinology & Metabolism

HCG Biology & Physiology

• Cole LA (2010) — "Biological functions of hCG and hCG-related molecules" — Reproductive Biology and Endocrinology

HCG Diet / Weight Loss Evidence

• Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G (1995) — "The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis" — British Journal of Clinical Pharmacology
• FDA: Questions and Answers on HCG Products for Weight Loss

Regulatory & Classification

• FDA: Transition of Biological Products (BPCIA Implementation)
• WADA: Prohibited List

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.